Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

Abstract

Results of this study indicated that single-agent erlotinib is well tolerated and has modest disease-control benefit in HCC, manifested as modestly prolonged PFS and OS when compared with historical controls.